ArticleBMC infectious diseases2022
Long-term outcome of lamivudine/dolutegravir dual therapy in HIV-infected, virologically suppressed patients.
Franco Maggiolo et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
11 papers cite it
this papertrialcites it